Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027GlobeNewsWire • Thursday
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell CarcinomaGlobeNewsWire • Thursday
Here Is Why Bargain Hunters Would Love Fast-paced Mover Fortress Biotech (FBIO)Zacks Investment Research • 07/15/24
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred StockGlobeNewsWire • 07/05/24
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 07/02/24
Checkpoint Therapeutics Announces Biologics License Application Resubmission for CosibelimabGlobeNewsWire • 07/02/24
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA ResubmissionGlobeNewsWire • 06/24/24
Fortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company ShowcaseGlobeNewsWire • 05/16/24
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/15/24
Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company ShowcaseGlobeNewsWire • 05/15/24
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver TransplantationGlobeNewsWire • 05/14/24
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/13/24
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceGlobeNewsWire • 05/13/24
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesGlobeNewsWire • 05/10/24
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024GlobeNewsWire • 05/07/24
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial OfficerGlobeNewsWire • 05/01/24
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024GlobeNewsWire • 04/25/24
Fortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/28/24
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/22/24
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/21/24
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaGlobeNewsWire • 03/18/24
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024GlobeNewsWire • 03/15/24